Drug firm BDR Pharmaceuticals on Wednesday said it has established its antifungal medication Favipiravir for treating COVID-19 patients in India at a cost of Rs 63 each tablet.

The business has also come up with a patient assistance programme which will allow patients and institutions who have limited resources to buy the medicine at an extremely subsidised rate, BDR Pharmaceuticals said in a statement.

BDR pharma has received an endorsement from the Drugs Controller General of India (DCGI) to fabricate Favipiravir to treat mild to moderate patients using COVID-19 symptoms.

The drug has been launched under the name'BDFAVI', it added.

"BDR has been in the forefront of benefiting patients in this pandemic and supporting India's struggle against COVID-19. This launching further strengthens our commitment to the patients to provide better results for patients with mild to moderate COVID symptoms in India," BDR Pharmaceuticals CMD Dharmesh Shah stated.

The company has developed Favipiravir tablets in 200 mg strengths with a strip of 10 tablets, BDR Pharmaceuticals said.